Post-COVID-19 Fungal Infection in the Aged Population
- PMID: 36992139
- PMCID: PMC10056493
- DOI: 10.3390/vaccines11030555
Post-COVID-19 Fungal Infection in the Aged Population
Abstract
Coronavirus disease 2019 (COVID-19) infection is currently a great cause of concern for the healthcare sector around the globe. SARS-CoV-2 is an RNA virus that causes a serious infection that is associated with numerous adverse effects and multiple complications associated with different organs and systems during its pathogenic cycle in humans. Individuals affected by COVID-19, especially elderly populations and immunocompromised people, are greatly vulnerable to opportunistic fungal pathogens. Aspergillosis, invasive candidiasis, and mucormycosis are widespread fungal coinfections in COVID-19 patients. Other fungal infections that are rare but are exhibiting increased incidence in the current scenario include infections caused by Pneumocystis jirovecii, Histoplasma sp., Cryptococcus sp., etc. By producing virulent spores, these pathogens increase the severity of the disease and increase the morbidity and fatality rates in COVID-19 patients globally. These infections generally occur in patients recovering from COVID-19 infection, resulting in rehospitalization. Older and immunocompromised individuals are at higher risk of developing opportunistic fungal infections. This review focuses on understanding the opportunistic fungal infections prevalent in COVID-19 patients, especially elderly people. We have also highlighted the important preventive methods, diagnostic approaches, and prophylactic measures for fungal infections.
Keywords: COVID-19; aspergillosis; coinfection; fungal infections; invasive candidiasis; mucormycosis.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Fungal pathogens and COVID-19.Curr Opin Microbiol. 2023 Oct;75:102365. doi: 10.1016/j.mib.2023.102365. Epub 2023 Aug 23. Curr Opin Microbiol. 2023. PMID: 37625261 Review.
-
The role of SARS-CoV-2 immunosuppression and the therapy used to manage COVID-19 disease in the emergence of opportunistic fungal infections: A review.Curr Res Biotechnol. 2022;4:337-349. doi: 10.1016/j.crbiot.2022.08.001. Epub 2022 Aug 3. Curr Res Biotechnol. 2022. PMID: 35942223 Free PMC article. Review.
-
Root Causes of Fungal Coinfections in COVID-19 Infected Patients.Infect Dis Rep. 2021 Dec 4;13(4):1018-1035. doi: 10.3390/idr13040093. Infect Dis Rep. 2021. PMID: 34940403 Free PMC article. Review.
-
Diagnostic Challenges in Fungal Coinfections Associated With Global COVID-19.Scientifica (Cairo). 2025 May 7;2025:6840605. doi: 10.1155/sci5/6840605. eCollection 2025. Scientifica (Cairo). 2025. PMID: 40370518 Free PMC article. Review.
-
High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections.Discoveries (Craiova). 2021 Mar 31;9(1):e126. doi: 10.15190/d.2021.5. Discoveries (Craiova). 2021. PMID: 34036149 Free PMC article. Review.
Cited by
-
Invasive Fungal Infections in Immunocompromised Conditions: Emphasis on COVID-19.Curr Microbiol. 2024 Oct 9;81(11):400. doi: 10.1007/s00284-024-03916-1. Curr Microbiol. 2024. PMID: 39384659 Review.
-
Identification and characterization of a novel antifungal compound tubeimoside I targeting cell wall.Microbiol Spectr. 2024 Jun 4;12(6):e0404723. doi: 10.1128/spectrum.04047-23. Epub 2024 Apr 23. Microbiol Spectr. 2024. PMID: 38651884 Free PMC article.
-
Role of TLR2 rs5743708 and dectin-1 rs16910526 polymorphisms in susceptibility to fungal infections in COVID-19 patients.Cent Eur J Immunol. 2025;50(1):77-86. doi: 10.5114/ceji.2025.149165. Epub 2025 May 5. Cent Eur J Immunol. 2025. PMID: 40620655 Free PMC article.
-
Insights on Covid-19 with superimposed pulmonary histoplasmosis: The possible nexus.Immun Inflamm Dis. 2023 Sep;11(9):e989. doi: 10.1002/iid3.989. Immun Inflamm Dis. 2023. PMID: 37773721 Free PMC article. Review.
-
Fungal Pulmonary Coinfections in COVID-19: Microbiological Assessment, Inflammatory Profiles, and Clinical Outcomes.Biomedicines. 2025 Apr 3;13(4):864. doi: 10.3390/biomedicines13040864. Biomedicines. 2025. PMID: 40299432 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous